Affimed Added to the Russell 2000®, 3000® and Microcap Indexes
July 01 2019 - 5:00AM
Heidelberg, Germany, July 1, 2019 - Affimed N.V.
(Nasdaq: AFMD), a clinical stage biopharmaceutical company
committed to giving patients back their innate ability to fight
cancer, today announced that it has been added to the Russell
2000®, Russell 3000®, and Russell Microcap® Indexes, effective
after the U.S. markets closed on Friday, June 28, 2019 as part of
Russell’s annual index rebalance process.
“We believe inclusion in the widely referenced
Russell U.S. Indexes, with some of the most innovative public
companies in the U.S., reflects Affimed’s substantial progress in
the last year and is a great opportunity to generate added
visibility and enhance exposure to investors,” said Dr. Adi Hoess,
Affimed’s CEO. “We look forward to the prospect of building on this
progress as we further advance our CD16A-targeting innate cell
engager product candidates, expand our clinical stage pipeline, and
explore rational combinations of our innate cell engagers with
other therapeutic modalities.”
Russell U.S. Indexes are widely used by
investment managers and institutional investors as the basis for
index funds and as benchmarks for active investment strategies.
Approximately $9 trillion in assets are benchmarked against Russell
U.S. Indexes.
For more information on the Russell U.S. Indexes
reconstitution, go to the "Russell Reconstitution" page at
https://www.ftserussell.com/index-series/index-resources/russell-reconstitution.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical stage
biopharmaceutical company committed to giving patients back their
innate ability to fight cancer. Affimed’s fit-for-purpose ROCK®
platform allows innate cell engagers to be designed for specific
patient populations. The Company is developing single and
combination therapies to treat cancers. For more information,
please visit www.affimed.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as "anticipate," "believe," "could," "estimate," "expect,"
"goal," "intend," "look forward to", "may," "plan," "potential,"
"predict," "project," "should," "will," "would" and similar
expressions. Forward-looking statements appear in a number of
places throughout this release and include statements regarding our
intentions, beliefs, projections, outlook, analyses and current
expectations concerning, among other things, the value of our ROCK®
platform, our ongoing and planned preclinical development and
clinical trials, our collaborations and development of our products
in combination with other therapies, the timing of and our ability
to make regulatory filings and obtain and maintain regulatory
approvals for our product candidates our intellectual property
position, our collaboration activities, our ability to develop
commercial functions, expectations regarding clinical trial data,
our results of operations, cash needs, financial condition,
liquidity, prospects, future transactions, growth and strategies,
the industry in which we operate, the trends that may affect the
industry or us and the risks uncertainties and other factors
described under the heading “Risk Factors” in Affimed’s filings
with the Securities and Exchange Commission. Given these risks,
uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new
information becomes available in the future.
Affimed Investor
Contact:Gregory Gin, Head of Investor RelationsE-Mail:
IR@affimed.com
Affimed Media Contact:Anca
Alexandru, Head of Communications, EU IRE-Mail:
media@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024